Abstract: This specification generally relates to an improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine (I), or pharmaceutically acceptable salts thereof, polymorphic forms thereof, and intermediates useful in the manufacture of such compounds and salts thereof.

Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.

Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.

Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.

Abstract: A compound of the formula (VIII) wherein each X is independently H or F; and R is selected from hydrogen, halogen, cyano, methyl, cyanomethyl, fluoromethyl, difluoromethyl, trifluoromethyl and —Si[(1-4C)alkyl]3; and processes for preparing a compound of formula (VIII) by bromination of a compound of the formula (VII),

Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.

Abstract: The invention relates to a process for the preparation of certain pyrimidinone compounds.

Abstract: The invention relates to a process for the preparation of certain pyrimidinone compounds.

Abstract: The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

Abstract: The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

Abstract: A compound of formula (I) or a salt thereof: wherein: P1 is pyridiyl; P2 is phenyl; A is a bond or a chain of 1 to 5 atoms optionally substituted by C1-6 alkyl; R1 and R2 groups are each independently hydrogen, C1-6alkyl optionally substituted by NR12R13, C2-6alkenyl, C2-6alkynyl, cyano, halogen, CF3, NR12R13, CHO, OCF3, COR14, CH2OR14 or OR14 where R12, R13 and R14 are independently hydrogen or C1-6alkyl; n and m are independently 0, 1 or 2; R3 is hydrogen or C1-6 alkyl; R4 is a group of formula (i): in which: R6 and R7 are independently hydrogen, C1-6 alkyl optionally substituted by one or more fluorine atoms, C1-6alkylthio, C1-6alkoxy or halogen.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:X--CO--CH.sub.2 --Z (I)whereinX is a monocyclic or polycyclic aromatic group,Z is of a linear, cyclic or bicyclic, aromatic or aliphatic moiety containing a nitrogen atom;and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

Abstract: A compound of formula (I) or a salt thereof: ##STR1## wherein: P.sup.1 is pyridyl;P.sup.2 is phenyl;A is a bond or a chain of 1 to 5 atoms optionally substituted by C.sub.1-6 alkyl;R.sup.1 and R.sup.2 groups are each independently hydrogen, C.sub.1-6 alkyl optionally substituted by NR.sup.12 R.sup.13, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, cyano, halogen, CF.sub.3, NR.sup.12 R.sup.13, CHO, OCF.sub.3, COR.sup.14, CH.sub.2 OR.sup.14 or OR.sup.14 where R.sup.12, R.sup.13 and R.sup.14 are independently hydrogen or C.sub.1-6 alkyl;n and m are independently 0, 1 or 2;R.sup.3 is hydrogen or C.sub.1-6 alkyl;R.sup.4 is a group of formula (i): ##STR2## in which: R.sup.6 and R.sup.7 are independently hydrogen, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, C.sub.1-6 alkylthio, C.sub.1-6 alkoxy or halogen.

Abstract: The invention relates to heterocyclic families of compounds having pharmacological activity, in particular possessing 5HT.sub.2C receptor antagonist activity processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

Abstract: Biphenyl amide derivatives as 5HT.sub.1D antagonists, processes for their preparation, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.

Abstract: Novel amide and urea derivatives, processes for their preparation, pharmaceutical compositions containing hem and their use as medicaments are disclosed.

Abstract: The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the treatment of artrial arrhythmia, stroke or CNS disordersX--CO--CH.sub.2 --Z (I)whereinX is a monocyclic or polycyclic aromatic group,Z is of sub-formula (h), (j) or (k): ##STR1## and wherein the remaining variables are as defined herein.

Abstract: Compounds of formula (I), or pharmaceutically acceptable salts thereof are provided: ##STR1## in which X.sub.1 --(CH.sub.2).sub.x --X.sub.2 forms a 5-7 membered ring wherein:X.sub.1 is O or S;X.sub.2 is O, S or NR wherein R is hydrogen;x is 1, 2 or 3;R.sub.1 is hydrogen, amino, halo, C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy;R.sub.2 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, amino or C.sub.1-6 alkylthio;R.sub.3 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or amino;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6 alkyl;Y is NH;Z is of sub-formula (a): ##STR2## wherein --(CH.sub.2).sub.n.sup.1 is attached at carbon; andn.sup.1 is 0, 1, 2, 3 or 4;q is 0, 1, 2 or 3;R.sub.a is (CH.sub.2).sub.n.sup.2 --R.sub.7 wherein n.sup.2 is 2 or 3 and R.sub.7 is selected from cyano, hydroxyl, C.sub.1-6 alkoxy, phenoxy, C(O)C.sub.1-6 alkyl, COC.sub.6 H.sub.5, --CONR.sub.8 R.sub.9, NR.sub.8 COR.sub.9, SO.sub.2 NR.sub.8 R.sub.9 or NR.sub.8 SO.sub.2 R.sub.9 whereinR.sub.8 and R.sub.